Robert A. Doody has served as Senior Vice President of Investor Relations for Prelude Therapeutics since 2004. He has over 25 years of communications leadership experience in pharma and biotech across numerous therapeutic sectors. Prior to joining Prelude, Mr. Doody has served as the Senior Investor Relations leader at Aclaris Therapeutics, Provention Bio, Idera Pharmaceuticals, and ViroPharma Incorporated. During his career, Mr. Doody has played instrumental roles in the raising of over $1 billion in capital and nearly $10 billion in shareholder value through mergers and acquisitions. Mr. Doody was recognized by IR Magazine as Best Investor Relations Professional and Best Investor Relations by a Company. Additionally, Mr. Doody served honorably in the United States Navy. He earned his communications degree from Rowan University.
Robert Doody
Awards won
Best investor relations officer (small cap)
2013
US
Explore
Articles
Stay informed on critical issues affecting IR teams, gain expert analysis of market trends, buy-side insights, career advice, and more.
Peer comparison
Our new tool lets you benchmark your IR program against peers in your region and sector, uncover strengths, and identify areas for growth.
Playbooks
Packed with industry trends and insights that define best-in-class practices across key, practical, and timely aspects of an IRO’s role.
Research reports
Powered by the world’s largest survey of the buy side, sell side, and IR professionals, discover data-driven insights on running a successful IR program.